Bmi Korea Co., Ltd

BMI KOREA: A DYNAMICALLY-GROWING BIOPHARMACEUTICAL COMPANY, ALWAYS CHALLENGING FOR HEALTHY LIFE OF HUMAN-BEING. BMI is a pharmaceutical and biotechnology company based in South Korea that focuses on development and commercialization of new medicines (incl. biologics) and medical devices. BMI started to operate in 2005, and for more than a decade it has been growing with successful development of new medicines and biologics based on its own novel technologies and know-hows. BMI has specialized in sterile formulation and has developed many products such as HA, PN, PDRN and Botulinum Toxin etc. One of main BMI’s assets is “Hyaluronidase”. BMI has led the market over the last 10 years with two formulations:(A liquid sterile-brand: “Hirax® and a lyophilized sterile power vial- brand: “BM Hylunidase ®”). With these experiences and expertise, BMI has recently developed new generation of it, “Recombinant Hyaluronidase” which is well-known to be used for changing monoclonal antibody’s formulation from IV to SC. On top of that, BMI provides integrated CDMO services to help other pharmaceuticals and biotech companies develop and commercialize medicines. With the most advanced cGMP facilities and R&D center in JEJU and OSONG, BMI can deliver the highly qualified DS, DP and ensure partners’ success to IND, NDA and BLA. Full of speed and customer tailored flexibility are the main strengths. For more information, please visit our website below: